 Life Science Investor Mandates (May 19 - May 25) |
| |
|
Raises New Impact Fund For Early Stage Oncology Drugs
|
Seeks Seed & Series A Deals in Connected Devices and Telemedicine
|
|
Invests In Data-Driven Healthcare and Robotics
|
|
Raises New Fund For Early Stage Therapeutics and Devices
|
|
|
 Medical robotics technology is changing the paradigm of surgery, prosthetics, rehabilitation, and many other medical disciplines. Entrepreneurs and investors are eyeing on the game-changing potential in both physicians' practice and patients' homes.
One example is the development of bionic limbs and exoskeletons. Such technology can be applied in various fields including amputees, persons with disability, and emergency response. The US Defense Advanced Research Projects Agency (DARPA) has recently launched new initiative to develop prosthetic limbs that feel and function like natural limbs for amputees. One of its grant awardees is a Utah-based company with an implantable wireless device that aims to increase reliability of prosthetic limbs and create a more natural movement...
|
 |
|
 Your fundraising efforts certainly won't slow down this summer, nor will the team at Life Science Nation. We're always on the clock, committed to providing early stage life science companies and investors with the critical data necessary to create compelling connections between technology and funding. In this spirit, LSN's Next Phase will be publishing one chapter each week of our hit book from last summer, The Life Science Executive's Fundraising Manifesto by Dennis Ford.
The Life Science Executive's Fundraising Manifesto helps scientists understand the fundamental skills needed to brand and market their companies. It discusses how to use a consistent message to achieve compelling results from a fundraising campaign and how to aggregate a list of potential global investors that are a fit for your company's products and services. The book also explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and ultimately secure capital allocations.
The LSN Summer Reading series begins with "The Legal Landscape: A Basic Overview." Contributed by Gerard P O'Connor, Esq, this first chapter provides a whistle-stop tour of all the legal issues a fundraising CEO needs to consider when raising capital...
|
|
|
Early Stage Therapeutic Investors
It is well known that early stage therapeutic companies require a significant source of funding due to the long road of development. Despite therapeutic companies' high-risk development timeline, many investors continue to remain focused on investing in biotechnology with a steadfast belief in the potential of the space.
For RESI on MaRS (June 23rd), LSN has assembled five highly experienced investors particularly interested in biotech therapeutics. Held in the heart of Canada's healthcare innovation hub, MaRS Discovery District, the Early Stage Therapeutic Investors Panel will be moderated by Cynthia Lavoie, Partner of TVM Capital, and will be joined by: - Benjamin Rovinski, Managing Director, Lumira Capital
- Kelly Holman, Co-Founder and Managing Director, Genesys Capital
- David O'Neill, Vice President, Business Development, Fight Against Cancer Innovation Trust
- Jennifer Hamilton, Senior Director, New Ventures (Canada), Johnson & Johnson
Incubators & Accelerators
It's a huge challenge to launch a healthcare startup, but an increasing number of incubators and accelerator programs are stepping up to support early stage entrepreneurs and provide services, facilities and capital to speed their paths to market.
Leaders from five of these organizations are gathering at RESI on MaRS to share their experience of working with very early stage companies, and to explore how a startup can work with an incubator or accelerator partner to get ahead on their development pathway.
The moderator, Rebecca Yu, Head of JLABS @ Toronto, will be joined by:
- Dianne Carmichael, Managing Director, MaRS Health Venture Services
- Christopher Kim, Partner, Novatio Ventures (Korea Seoul Life Science Fund)
- Linda Maxwell, Director, BioMedical Zone
- Gordon Kurtenbach, Senior Director of Research, Autodesk
|
|
|
|
|
|
